Clinuvel Pharmaceuticals Limited
- Jurisdiction
Australia - LEI
5299004VJH3VCYLK6519 - ISIN
AU000000CUV3 (CUV.AX )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€49.19 632.6% undervalued - Fundamental strength relative to industry (Mohanram G-Value)
-
6
/ 7
Profile
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Read full profile
Fundamentals
- Net revenue
€102.32M - Gross margin
76.8% - EBIT
€48.96M - EBIT margin
47.9% - Net income
€40.22M - Net margin
39.3%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
- Last dividend amount
-
A$0.05 - Ex date
-
- Payment date
-
- Dividend payout ratio
-
6.9%
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Earnings Calls
Latest earnings call: August 28, 2025 (Q4 2025)